In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
1
0
0
0
Last 30D
1
0
0
0
0
1M Ago
1
1
0
0
0
2M Ago
0
0
0
0
0
3M Ago
3
0
0
0
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Mike Matson
Needham
Lowers
Buy
$40.00
$46.00
Suraj Kalia
Oppenheimer
Announces
Outperform
$32.00
-
Mike Matson
Needham
Maintains
Buy
$46.00
-
Danielle Antalffy
UBS
Raises
Buy
$58.00
$57.00
Rick Wise
Stifel
Lowers
Buy
$42.00
$50.00
Mike Matson
Needham
Raises
Buy
$46.00
$44.00
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the ...Full story available on Benzinga.com
Benzinga
